AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3146989 — intervention group
Group type: COMPARATOR
Intervention: Digoxin and disopyramide
Number of subjects: 56
Study 29278870 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization exercises including motor control training (n=11)
Number of subjects: 21
Study 29278870 — intervention group
Group type: COMPARATOR
Intervention: Strengthening exercises for back muscles, abdominal muscles, and hip muscles (Control group, n=10)
Number of subjects: 21
Study 28877510 — intervention group
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA
Number of subjects: 10
Study 28877510 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 10
Study 24771228 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital pulp therapy using calcium-enriched mixture cement (VPT/CEM)
Number of subjects: 407
Study 24771228 — intervention group
Group type: COMPARATOR
Intervention: Root canal therapy (RCT)
Number of subjects: 407
Study 23153963 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400mg daily intravenous for 5-14 days)
Number of subjects: 699
Study 23153963 — intervention group
Group type: COMPARATOR
Intervention: Ertapenem (1g daily intravenous for 5-14 days)
Number of subjects: 699
Study 23153963 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 699
Study 23153963 — intervention group
Group type: COMPARATOR
Intervention: Ertapenem
Number of subjects: 699
Study 21714645 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro with 5 μg/mL rHuPH20
Number of subjects: 0
Study 21714645 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular insulin with 5 μg/mL rHuPH20
Number of subjects: 0
Study 21714645 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro
Number of subjects: 0
Study 19418937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar)
Number of subjects: 0
Study 19418937 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 16896576 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 63
Study 16896576 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 63
Study 16281587 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% azelaic acid gel
Number of subjects: 580
Study 16281587 — intervention group
Group type: COMPARATOR
Intervention: 5% benzoyl peroxide (BPO)
Number of subjects: 580
Study 16281587 — intervention group
Group type: COMPARATOR
Intervention: 1% clindamycin
Number of subjects: 580
Study 11561268 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg/kg
Number of subjects: 46
Study 11561268 — intervention group
Group type: COMPARATOR
Intervention: No clonidine (Control)
Number of subjects: 46
Study 9598255 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg.kg‐1)
Number of subjects: 60
Study 9598255 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (5 mg.kg‐1)
Number of subjects: 60
Study 9598255 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone plus Atracurium (5 mg.kg‐1 thiopentone plus 0.05 mg.kg‐1 atracurium)
Number of subjects: 60
Study 7945786 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsam of Peru (225 mg)
Number of subjects: 11
Study 7945786 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural vanilla (50 mg)
Number of subjects: 11
Study 7945786 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial vanillin (12.5 mg)
Number of subjects: 11
Study 7945786 — intervention group
Group type: EXPERIMENTAL
Intervention: Eviction of food flavouring agents
Number of subjects: 11
Study 3345963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral coping skills training in a group setting
Number of subjects: 0
Study 3345963 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 31492147 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive Use Stigma (CUS) scale
Number of subjects: 633
Study 31492147 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents Stigmatizing Attitudes, Beliefs and Action (ASABA) scale
Number of subjects: 633
Study 28235882 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA) at a dose of 2 mg/kg every 3 weeks by intravenous infusion
Number of subjects: 89
Study 28235882 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA)
Number of subjects: 89
Study 25352527 — intervention group
Group type: EXPERIMENTAL
Intervention: keepin' it REAL program (implemented in 7th grade)
Number of subjects: 581
Study 25352527 — intervention group
Group type: COMPARATOR
Intervention: treatment-as-usual condition
Number of subjects: 581
Study 23944211 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolised care (using minimally invasive haemodynamic monitoring)
Number of subjects: 0
Study 23944211 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 21765074 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 370
Study 21765074 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B followed by fluconazole
Number of subjects: 370
Study 21765074 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ocular involvement)
Number of subjects: 370
Study 19687393 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency treatment
Number of subjects: 80
Study 19687393 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency treatment
Number of subjects: 80
Study 19687393 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery treatment
Number of subjects: 80
Study 19687393 — intervention group
Group type: COMPARATOR
Intervention: Partial inferior turbinotomy
Number of subjects: 80
Study 16506681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised lignocaine
Number of subjects: 0
Study 16506681 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 14716702 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Interview for Cognitive Status (TICS)
Number of subjects: 64
Study 14716702 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Telephone Interview for Cognitive Status (TICSm)
Number of subjects: 64
Study 14716702 — intervention group
Group type: COMPARATOR
Intervention: R-CAMCOG
Number of subjects: 64
Study 11075313 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg once daily for 7 days
Number of subjects: 12
Study 11075313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15321290 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with intermittent injection through the epidural needle
Number of subjects: 88
Study 15321290 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia via a previously placed catheter
Number of subjects: 88
Study 1396287 — intervention group
Group type: EXPERIMENTAL
Intervention: Osterprem
Number of subjects: 30
Study 1396287 — intervention group
Group type: COMPARATOR
Intervention: Prematil
Number of subjects: 30
Study 3929127 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Nursing Intervention
Number of subjects: 0
Study 3929127 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Personalized Nursing Intervention)
Number of subjects: 0
Study 3929127 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Nursing Intervention with network participation
Number of subjects: 0
Study 31397413 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive self-ligating system
Number of subjects: 60
Study 31397413 — intervention group
Group type: COMPARATOR
Intervention: Conventional appliances
Number of subjects: 60
Study 30589029 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D + S (Dexmedetomidine + Sevoflurane)
Number of subjects: 120
Study 30589029 — intervention group
Group type: COMPARATOR
Intervention: Group M + S (Sevoflurane)
Number of subjects: 120
Study 30589029 — intervention group
Group type: COMPARATOR
Intervention: Group M + P (Control group with no dexmedetomidine)
Number of subjects: 120
Study 25011935 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) treatment
Number of subjects: 744
Study 23411674 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific interaction causing the sound (e.g. trickling)
Number of subjects: 0
Study 23411674 — intervention group
Group type: COMPARATOR
Intervention: More general descriptions (e.g. pour, liquid)
Number of subjects: 0
Study 23411674 — intervention group
Group type: COMPARATOR
Intervention: More detailed descriptions using adverbs (e.g. trickling evenly)
Number of subjects: 0
Study 21477273 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based mentoring service
Number of subjects: 195
Study 21477273 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched participants from general practice)
Number of subjects: 195
Study 20016179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive fluoride 5% sodium varnish regimen (three applications/2 weeks)
Number of subjects: 600
Study 20016179 — intervention group
Group type: COMPARATOR
Intervention: Standard semiannual application of fluoride varnish (one active and two placebo treatments every 6 months)
Number of subjects: 600
Study 18085143 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at point 'Xiajiquan' plus standard acupoints (Quchi, Shousanli, Waiguan)
Number of subjects: 123
Study 18085143 — intervention group
Group type: COMPARATOR
Intervention: Standard acupuncture at Quchi (LI 11), Shousanli (LI 10), Waiguan (TE 5)
Number of subjects: 123
Study 15200736 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation of sumatriptan 50 mg
Number of subjects: 32
Study 15200736 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation of sumatriptan 100 mg
Number of subjects: 32
Study 15200736 — intervention group
Group type: COMPARATOR
Intervention: Conventional sumatriptan tablets
Number of subjects: 32
Study 11575388 — intervention group
Group type: EXPERIMENTAL
Intervention: Combitube (37Fr) small adult
Number of subjects: 40
Study 11575388 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube
Number of subjects: 40
Study 9835439 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Placebo
Number of subjects: 173
Study 9835439 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Salbutamol
Number of subjects: 173
Study 9835439 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Beclomethasone
Number of subjects: 173
Study 9835439 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone + Salbutamol
Number of subjects: 173
Study 9776856 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned media from non-insulin-dependent diabetes mellitus wound fibroblasts
Number of subjects: 2
Study 9776856 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of 6 mmol/L l-lactate to uninjured normal fibroblasts
Number of subjects: 2
Study 9776856 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing d-glucose in the media
Number of subjects: 2
Study 9776856 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with beta-hydroxybutyrate on uninjured normal cells
Number of subjects: 2
Study 1652976 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential use of Tamoxifen, Premarin, and chemotherapy
Number of subjects: 0
Study 1652976 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH agonists and tamoxifen
Number of subjects: 0
Study 1652976 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide
Number of subjects: 0
Study 1652976 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-OHA
Number of subjects: 0
Study 1652976 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene and RU486
Number of subjects: 0
Study 1652976 — intervention group
Group type: EXPERIMENTAL
Intervention: New hormonal agents
Number of subjects: 0
Study 1652976 — intervention group
Group type: COMPARATOR
Intervention: Combination of chemotherapy and hormonal therapy
Number of subjects: 0
Study 6684029 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous protocol (C)
Number of subjects: 20
Study 6684029 — intervention group
Group type: COMPARATOR
Intervention: Discontinuous protocol (D)
Number of subjects: 20
Study 30781525 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention group
Number of subjects: 334
Study 30781525 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 334
Study 31105911 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Self-Change (GSC)
Number of subjects: 57
Study 31105911 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GSC-NRT
Number of subjects: 57
Study 31105911 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 57
Study 26630949 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM nursing package, resource-oriented counseling, evidence-based information material on CAM
Number of subjects: 0
Study 24423336 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 231
Study 24423336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 22172901 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adjuvant radiotherapy (HD-ART) with androgen deprivation therapy (ADT)
Number of subjects: 225
Study 22172901 — intervention group
Group type: COMPARATOR
Intervention: High-dose adjuvant radiotherapy (HD-ART) without androgen deprivation therapy (ADT)
Number of subjects: 225
Study 22172901 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy at the time of RP
Number of subjects: 225
Study 22172901 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adjuvant radiotherapy (HD-ART)
Number of subjects: 225
Study 20483660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 1 mg
Number of subjects: 110
Study 20483660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 4 mg
Number of subjects: 110
Study 20483660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 110
Study 20483660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 18760136 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg twice a day
Number of subjects: 174
Study 18760136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 16137513 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/day)
Number of subjects: 14
Study 16137513 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 14
Study 12416358 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 25 to 30 mg/kg daily for 2 months
Number of subjects: 60
Study 12416358 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 60
Study 9809089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent negative pressure ventilation (INPV)
Number of subjects: 38
Study 9809089 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous assisted ventilation (SAV)
Number of subjects: 38
Study 8062954 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin [INN]
Number of subjects: 150
Study 8062954 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin acetate
Number of subjects: 150
Study 8062954 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) and hMG
Number of subjects: 150
Study 8062954 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 150
Study 3055874 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg mifentidine
Number of subjects: 9
Study 3055874 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg mifentidine
Number of subjects: 9
Study 3055874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29529919 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinect-based VR training + Physical Therapy (PT)
Number of subjects: 0
Study 29529919 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy (PT) only
Number of subjects: 0
Study 28266243 — intervention group
Group type: EXPERIMENTAL
Intervention: PASI 90-100 responders at week 12
Number of subjects: 0
Study 28266243 — intervention group
Group type: EXPERIMENTAL
Intervention: PASI 90-100 responders at week 52
Number of subjects: 0
Study 28266243 — intervention group
Group type: EXPERIMENTAL
Intervention: IGA ratings of Clear or Almost Clear
Number of subjects: 0
Study 28266243 — intervention group
Group type: COMPARATOR
Intervention: PASI 75-89 responders
Number of subjects: 0
Study 25333885 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 151
Study 25333885 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 151
Study 23540216 — intervention group
Group type: EXPERIMENTAL
Intervention: RehaCom rehabilitation programme
Number of subjects: 81
Study 23540216 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RehaCom training)
Number of subjects: 81
Study 21174253 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing Dr. Kawashima's Brain Training on a Nintendo DS handheld console for 10 days post-surgery.
Number of subjects: 32
Study 21174253 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video games).
Number of subjects: 32
Study 21174253 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control).
Number of subjects: 32
Study 18811813 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic navigation (Niobe system and Helios II catheter)
Number of subjects: 71
Study 18811813 — intervention group
Group type: COMPARATOR
Intervention: Manual navigation
Number of subjects: 71
Study 18811813 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic navigation
Number of subjects: 71
Study 16896731 — intervention group
Group type: EXPERIMENTAL
Intervention: Equitation training for 14 weeks, 5 days/week
Number of subjects: 25
Study 16896731 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 12672309 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 microg daily for adults, 200 microg for children younger than 11 years)
Number of subjects: 7241
Study 12672309 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 7241
Study 12672309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7241
Study 11091231 — intervention group
Group type: EXPERIMENTAL
Intervention: QUOROM statement checklist
Number of subjects: 30
Study 11091231 — intervention group
Group type: EXPERIMENTAL
Intervention: QUOROM statement flow diagram
Number of subjects: 30
Study 8675160 — intervention group
Group type: EXPERIMENTAL
Intervention: [(13)C 3‐methyl] caffeine breath test (CBT) administered to 20 patients at a dosage of 2 mg/kg
Number of subjects: 37
Study 8675160 — intervention group
Group type: COMPARATOR
Intervention: Commercially available CBT kit with a constant 200-mg dose administered to 17 patients
Number of subjects: 37
Study 8675160 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized-dose CBT
Number of subjects: 37
Study 1562332 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzonatate 200 mg topically for oropharyngeal anesthesia
Number of subjects: 40
Study 1562332 — intervention group
Group type: COMPARATOR
Intervention: Bilateral superior laryngeal nerve blocks (total 8 ml of 1% lidocaine) and 2 ml of 20% benzocaine orally
Number of subjects: 40
Study 1562332 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups administered 4 ml of 4% lidocaine translaryngeally
Number of subjects: 40
Study 1562332 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 2866725 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine (topical eye drops)
Number of subjects: 40
Study 2866725 — intervention group
Group type: COMPARATOR
Intervention: Placebo (topical eye drops)
Number of subjects: 40
Study 30219436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo Leaf Tablets and Liuwei Dihuang Pills
Number of subjects: 140
Study 30219436 — intervention group
Group type: COMPARATOR
Intervention: Placebos of Ginkgo Leaf Tablets and Liuwei Dihuang Pills
Number of subjects: 140
Study 26059745 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of extracts from grape seed and skin (330 mg), green tea (100 mg), resveratrol (60 mg), quercetin, ginkgo biloba and bilberry (60 mg)
Number of subjects: 18
Study 26059745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 26059745 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of extracts from grape seed and skin, green tea, resveratrol, quercetin, ginkgo biloba and bilberry
Number of subjects: 18
Study 25371542 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit-vessel intervention (CVI)
Number of subjects: 3984
Study 23059776 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance pemetrexed 500 mg/m plus best supportive care
Number of subjects: 539
Study 23059776 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 539
Study 23059776 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance pemetrexed
Number of subjects: 539
Study 23059776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study 20662624 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6 516/983 genotype
Number of subjects: 821
Study 20662624 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow‐metabolizer genotypes
Number of subjects: 821
Study 18703166 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive outpatient educational intervention
Number of subjects: 0
Study 15968496 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammograms highly suggestive of malignancy (category 5)
Number of subjects: 7670
Study 15968496 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspicious mammograms (category 4)
Number of subjects: 7670
Study 15968496 — intervention group
Group type: EXPERIMENTAL
Intervention: Other mammography assessments (categories 0-3)
Number of subjects: 7670
Study 15968496 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a lump, absence of mammogram calcifications
Number of subjects: 7670
Study 11967719 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt intake (20 mmol/day)
Number of subjects: 29
Study 11967719 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide administration (40 mg/8 h orally)
Number of subjects: 29